Updated data presented at ASH 2025 set the clinical bar Lyell now intends to clear in registration: in third-line-plus large B-cell lymphomaB-cell lymphoma, ronde-cel produced a 93% best overall response rate and 76% complete responses in 29 efficacy-evaluable patients, with median progression-free survival of 18 months at cutoff. In a smaller second-line cohort, best overall response reached 83% with 61% complete responses. Among 25 patients given dexamethasone prophylaxis, there were no grade ≥3 CRS events and 4% grade ≥3 ICANS, supporting outpatient administration in select settings.
Against that backdrop, Lyell has dosed the first patient in PiNACLE – H2H, a Phase 3, head-to-head randomized trial pitting its dual-targeted CD19/CD20 product ronde-cel against investigator’s choice of two entrenched CD19 CAR Ts, liso-cel or axi-cel, in second-line relapsed/refractory LBCL. The superiority study targets roughly 400 patients across U.S., Canada, and Australia, uses event-free survival as the primary endpoint, and standardizes ronde-cel dosing at 100 million CAR T cells with inpatient or outpatient administration permitted. In parallel, Lyell is running PiNACLE, a single-arm pivotal study in the third-line-plus setting (~120 patients, ORR primary endpoint), with a U.S. BLA submission planned for 2027.
Strategically, Lyell is stepping directly into the turf defined by ZUMA-7 and TRANSFORM with a design few sponsors have attempted in cellular therapy: a randomized head-to-head against commercial incumbents. The bet is twofold. First, dual antigen targeting with an OR logic gate may mitigate CD19 antigen escape and lift complete response durability relative to single-target CD19 products. Second, a safety profile managed proactively with steroid prophylaxis could shift more care to outpatient settings, easing capacity constraints that continue to throttle CAR T utilization. The company is also signaling operational readiness, pointing to a dedicated manufacturing center it says can support commercial-scale volumes, a prerequisite if a positive 2L readout triggers rapid demand.
For sites, this protocol adds uncommon operational complexity. Investigators must run three distinct autologous supply chains under one trial—coordinating leukapheresis, vein-to-vein timelines, cryostorage, and REMS requirements that differ across products—while standardizing bridging, steroid prophylaxis, and toxicity grading to preserve trial integrity. Pharmacy, ICU, and apheresis resources will need harmonized scheduling to avoid delays that could bias EFS. CROs face parallel challenges in logistics orchestration and data harmonization for inpatient versus outpatient care pathways.
Regulators and payers stand to gain the first rigorous comparative dataset among CAR Ts in 2L LBCL, potentially informing label nuance, sequencing, and value frameworks beyond indirect cross-trial comparisons. If outpatient administration proves sustainable without efficacy trade-offs, total cost of care and site economics could shift meaningfully. For sponsors of single-target products, the trial introduces headwind risk if dual targeting shows clear superiority on EFS or neurotoxicity rates.
What to watch next: enrollment velocity in a competitive 2L landscape where commercial options are readily available; protocol discipline around bridging therapy and time-to-infusion, both material to EFS; interim safety looks for grade ≥3 CRS/ICANS with steroid prophylaxis and any signal of efficacy attenuation; and operational readouts such as hospitalization rates and ICU utilization. On the 3L+ path, ORR alone will not carry approval without durability, so 12-month CR maintenance and updated PFS will be pivotal to the planned 2027 submission. If PiNACLE – H2H reads out positive, expect rapid moves to align manufacturing capacity, payer engagement on outpatient reimbursement, and potential recalibration by incumbents to defend share with real-world evidence and combination strategies.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
